Selected research
Market Structure
Global Bupivacaine Extended-Release Liposome Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Bupivacaine Extended-Release Liposome Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Bupivacaine Extended-Release Liposome Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Bupivacaine Extended-Release Liposome Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Bupivacaine Extended-Release Liposome Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Bupivacaine Extended-Release Liposome Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Bupivacaine Extended-Release Liposome Injection include Pacira Pharmaceuticals and Jiangsu Hengrui Pharm among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Bupivacaine Extended-Release Liposome Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Bupivacaine Extended-Release Liposome Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Bupivacaine Extended-Release Liposome Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Bupivacaine Extended-Release Liposome Injection market size, projected growth trends, production technologies, key applications, and end-use industries.
Bupivacaine Extended-Release Liposome Injection Segment by Company
Pacira Pharmaceuticals
Jiangsu Hengrui Pharm
Bupivacaine Extended-Release Liposome Injection Segment by Type
133mg Per Vial
266mg Per Vial
Bupivacaine Extended-Release Liposome Injection Segment by Application
Local Anesthesia
Postoperative Analgesia
Other
Bupivacaine Extended-Release Liposome Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bupivacaine Extended-Release Liposome Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bupivacaine Extended-Release Liposome Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bupivacaine Extended-Release Liposome Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Bupivacaine Extended-Release Liposome Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bupivacaine Extended-Release Liposome Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bupivacaine Extended-Release Liposome Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Bupivacaine Extended-Release Liposome Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- 133mg Per Vial
- 266mg Per Vial
Applications
- Local Anesthesia
- Postoperative Analgesia
- Other
Companies covered
- Pacira Pharmaceuticals
- Jiangsu Hengrui Pharm
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Bupivacaine Extended-Release Liposome Injection Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Bupivacaine Extended-Release Liposome Injection Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Bupivacaine Extended-Release Liposome Injection Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Bupivacaine Extended-Release Liposome Injection Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Bupivacaine Extended-Release Liposome Injection Market Dynamics
- 2.1 Bupivacaine Extended-Release Liposome Injection Industry Trends
- 2.2 Bupivacaine Extended-Release Liposome Injection Industry Drivers
- 2.3 Bupivacaine Extended-Release Liposome Injection Industry Opportunities and Challenges
- 2.4 Bupivacaine Extended-Release Liposome Injection Industry Restraints
3 Bupivacaine Extended-Release Liposome Injection Market by Manufacturers
- 3.1 Global Bupivacaine Extended-Release Liposome Injection Revenue by Manufacturers (2021-2026)
- 3.2 Global Bupivacaine Extended-Release Liposome Injection Sales by Manufacturers (2021-2026)
- 3.3 Global Bupivacaine Extended-Release Liposome Injection Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Bupivacaine Extended-Release Liposome Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Bupivacaine Extended-Release Liposome Injection Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Bupivacaine Extended-Release Liposome Injection Manufacturers, Product Type & Application
- 3.7 Global Bupivacaine Extended-Release Liposome Injection Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Bupivacaine Extended-Release Liposome Injection Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Bupivacaine Extended-Release Liposome Injection Players Market Share by Revenue in 2025
- 3.8.3 2025 Bupivacaine Extended-Release Liposome Injection Tier 1, Tier 2, and Tier 3
4 Bupivacaine Extended-Release Liposome Injection Market by Type
- 4.1 Bupivacaine Extended-Release Liposome Injection Type Introduction
- 4.1.1 133mg Per Vial
- 4.1.2 266mg Per Vial
- 4.2 Global Bupivacaine Extended-Release Liposome Injection Sales by Type
- 4.2.1 Global Bupivacaine Extended-Release Liposome Injection Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Bupivacaine Extended-Release Liposome Injection Sales by Type (2021-2032)
- 4.2.3 Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Type (2021-2032)
- 4.3 Global Bupivacaine Extended-Release Liposome Injection Revenue by Type
- 4.3.1 Global Bupivacaine Extended-Release Liposome Injection Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Bupivacaine Extended-Release Liposome Injection Revenue by Type (2021-2032)
- 4.3.3 Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Type (2021-2032)
5 Bupivacaine Extended-Release Liposome Injection Market by Application
- 5.1 Bupivacaine Extended-Release Liposome Injection Application Introduction
- 5.1.1 Local Anesthesia
- 5.1.2 Postoperative Analgesia
- 5.1.3 Other
- 5.2 Global Bupivacaine Extended-Release Liposome Injection Sales by Application
- 5.2.1 Global Bupivacaine Extended-Release Liposome Injection Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Bupivacaine Extended-Release Liposome Injection Sales by Application (2021-2032)
- 5.2.3 Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Application (2021-2032)
- 5.3 Global Bupivacaine Extended-Release Liposome Injection Revenue by Application
- 5.3.1 Global Bupivacaine Extended-Release Liposome Injection Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Bupivacaine Extended-Release Liposome Injection Revenue by Application (2021-2032)
- 5.3.3 Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Application (2021-2032)
6 Global Bupivacaine Extended-Release Liposome Injection Sales by Region
- 6.1 Global Bupivacaine Extended-Release Liposome Injection Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Bupivacaine Extended-Release Liposome Injection Sales by Region (2021-2032)
- 6.2.1 Global Bupivacaine Extended-Release Liposome Injection Sales by Region (2021-2026)
- 6.2.2 Global Bupivacaine Extended-Release Liposome Injection Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Bupivacaine Extended-Release Liposome Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Bupivacaine Extended-Release Liposome Injection Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Bupivacaine Extended-Release Liposome Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Bupivacaine Extended-Release Liposome Injection Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Bupivacaine Extended-Release Liposome Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Bupivacaine Extended-Release Liposome Injection Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Bupivacaine Extended-Release Liposome Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Bupivacaine Extended-Release Liposome Injection Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Bupivacaine Extended-Release Liposome Injection Revenue by Region
- 7.1 Global Bupivacaine Extended-Release Liposome Injection Revenue by Region
- 7.1.1 Global Bupivacaine Extended-Release Liposome Injection Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Bupivacaine Extended-Release Liposome Injection Revenue by Region (2021-2026)
- 7.1.3 Global Bupivacaine Extended-Release Liposome Injection Revenue by Region (2027-2032)
- 7.1.4 Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Bupivacaine Extended-Release Liposome Injection Revenue (2021-2032)
- 7.2.2 North America Bupivacaine Extended-Release Liposome Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Bupivacaine Extended-Release Liposome Injection Revenue (2021-2032)
- 7.3.2 Europe Bupivacaine Extended-Release Liposome Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Revenue (2021-2032)
- 7.4.2 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Bupivacaine Extended-Release Liposome Injection Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Bupivacaine Extended-Release Liposome Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Pacira Pharmaceuticals
- 8.1.1 Pacira Pharmaceuticals Company Information
- 8.1.2 Pacira Pharmaceuticals Business Overview
- 8.1.3 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Product Portfolio
- 8.1.5 Pacira Pharmaceuticals Recent Developments
- 8.2 Jiangsu Hengrui Pharm
- 8.2.1 Jiangsu Hengrui Pharm Company Information
- 8.2.2 Jiangsu Hengrui Pharm Business Overview
- 8.2.3 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Product Portfolio
- 8.2.5 Jiangsu Hengrui Pharm Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Bupivacaine Extended-Release Liposome Injection Value Chain Analysis
- 9.1.1 Bupivacaine Extended-Release Liposome Injection Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Bupivacaine Extended-Release Liposome Injection Production Mode & Process
- 9.2 Bupivacaine Extended-Release Liposome Injection Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Bupivacaine Extended-Release Liposome Injection Distributors
- 9.2.3 Bupivacaine Extended-Release Liposome Injection Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst